To Study Thyroid Function and Lipid Profile Levels in Chronic Kidney Disease Patients in a Tertiary Care Hospital of North India

Author(s): Navjot Kaur Layal1, Tejinder Sikri2, Jaskiran Kaur3, Jasmine Kaur4, Hardeep Singh Deep5

Chronic kidney disease (CKD) includes a spectrum of different pathophysiology
processes associated with abnormal kidney function, and a progressive decline in
GFR. Progression of CKD is associated with having a number of complications,
including thyroid dysfunction, dyslipidaemia, and cardiovascular diseases.
The present study was conducted among 60 CKD patients (cases) and 60 healthy
controls to compare their thyroid and lipid profile, who attended the Department
of Medicine in SGRDIMSR, Sri Amritsar from January 2019 to December
2020.These 60 CKD patients were grouped as group A. Group A was further
divided into various stages as per KIDGO staging according to GFR. 60 healthy
individuals were taken as controls and were kept as Group B. Demographic
features (age and sex) and medical history of diabetes mellitus, hypertension were
noted and blood samples (5mL) were analysed for blood urea, serum creatinine,
free triiodothyronine (T3), free thyroxine (T4), thyroid stimulating hormone (TSH),
total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL),
very low density lipoprotein (VLDL) and triglycerides.
Thyroid dysfunction was observed in patients of CKD, the most common being
overt hypothyroidism (56.6 %) followed by subclinical hypothyroidism (16.6 %),
low T3 (15 %), and hyperthyroidism (1.6 %). Hypercholesterolemia, low HDL,
elevated LDL, VLDL and triglyceride levels were observed in 74.9 %, 85.0 %, 38.3
%, 41.6 % and 76.6 % patients, respectively. Patients with CKD with 5 had
significantly higher risk of having thyroid dysfunction and dyslipidaemia as
compared to patients with stage 3 and 4.
Thyroid dysfunction and dyslipidaemia were common in patients with CKD.
Prevalence of hypothyroidism, dyslipidaemia increases with progression of CKD.
Hence early detection of thyroid dysfunction and dyslipidaemia is imperative to
improve mortality and morbidity of CKD patients.